{"name":"Kala Bio","slug":"kala-bio","ticker":"KALA","exchange":"NASDAQ","domain":"kalarx.com","description":"Kala Pharmaceuticals is a biopharmaceutical company focused on the development of innovative therapies for ophthalmology and gene therapy. The company's lead product, Eysuvis, is a corticosteroid for the treatment of postoperative inflammation following ocular surgery. Kala has a strong pipeline of gene therapy candidates, including KPL-404 for inherited retinal diseases. The company is well-positioned to capitalize on the growing demand for ophthalmology treatments.","hq":"Arlington, MA","founded":2015,"employees":"~350","ceo":"Mark Iwicki","sector":"Ophthalmology / Gene Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"2.3B","metrics":{"revenue":5000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Eysuvis patent cliff ($0.0B at risk)","drug":"Eysuvis","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Kala Pharmaceuticals reported fourth quarter and full year 2023 financial results, with net loss of $34.9 million and $144.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"regulatory","headline":"Kala Pharmaceuticals Announces FDA Approval of Eysuvis for Postoperative Inflammation Following Ocular Surgery","summary":"Kala Pharmaceuticals announced that the FDA has approved Eysuvis for the treatment of postoperative inflammation following ocular surgery.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"deal","headline":"Kala Pharmaceuticals Announces Collaboration with Regeneron Pharmaceuticals to Develop Gene Therapy for Inherited Retinal Diseases","summary":"Kala Pharmaceuticals announced a collaboration with Regeneron Pharmaceuticals to develop a gene therapy for inherited retinal diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxQWUkwdVBidjB6OElEcmN3SHlWWXZDUWpJUG5oUDF0U0VKTEZNbWJPeHBqVHJaWjZoSjFCUUo3VWpxQlBrTGp2WFVLQnNLVjVxcnc0S3lsSTlvTjk3MkdRd29zY1VfRnV6bE9HWXpIN0djUXZqUnhjN1BldmxYSmNuNkNoVklySVpCQkhwVnZIUlE0dG9ubWdzNWNkdTUwVFplLWs0Wm0tcHp6R0p0eTVrVF9zTmFlN0RWUExXVVJvemNvU1pEVG5yWUt0bGk0S0RyT2wzbHNnbGlHc2VRY0llanRvOUZWWTNrUUFFYUpoYU1aX3JJci1XWXg5YWdLczBQdmxhdUdySHl6NzBvekZsa2NSbjFvbTZoNE9XZFh3eTdBX2czcXdLX3AxdXFocVk?oc=5","date":"2026-03-31","type":"pipeline","source":"Barchart","summary":"Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - Barchart","headline":"Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNMHQyWGVNM0p2a2lkOXNUb2prUkswdUxRYUlLbndBOTFiRzd5UVlMN09yQnEyQ2RlVkVwM2JodjlYUjA5NnJqSVVEc0xxNGRYckVwbDVDMFRDU2FqSnR2QVZyVF9vUERDbGI5SEt6X3hCcThqS1VRY01RdURDbWZrdFB1c2JYWFhmOGlPWXdRODZSVmVkQ01WaUdoVnppa1gtZEVaUG1BTmREdDJhX1dqMVFwNGVhSDE2ZnlmVDVDTDRaNnExZlhEcFRNcEdPLUV1?oc=5","date":"2026-03-30","type":"earnings","source":"Sahm","summary":"EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch - Sahm","headline":"EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1WVmlTNXoza0VDbDhzNjROTGhlMmxsVk9saEJicFJtRkJFRFFYdlpIdFVGLU50d1hMX0I5Q1FnWnhtUDVjeklvTUdOMWpocUJ0R24tZnc5enc5SGs2UkRjQzZiRVYzbzI1dEV3Z1V3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan","headline":"If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNeGdvaHhLUXR6OHJPQnRyU2pBT1AwVnhxZnV1TlBHOVU1T1VfUjc5TW5fZzRVYTV5ZXJRYnRqcF82RWctOFNTR3JURVJNc2tlMS13dUFOd3QtWk44ZTFqWC1SeXJFcTNxcTkwNFVWU09CdEVDRXYwbk91MDNhM04xYU94YTFQQTZ0WmJrajJEM3k4bkFJOUJLaHc0MFNLNEc0VUJ5TnhKUmJwY0E2MEVfV0kyQ1UtLVlqVnMybkJQRQ?oc=5","date":"2026-03-11","type":"pipeline","source":"Stock Titan","summary":"$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan","headline":"$180B AI healthcare play: KALA BIO pivots with first agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9EeGgxTVhJc1BFVWZIUUlVcjFzTm5TOXlyTmxKSTFqYW5kYWVyLV9YblEzYy1NbHBFcmtZQUI1a2czckxicmZES2xMbDdWQzdqZFN3VVFkX0ZuLU5EcjRzbFNvTmgwX3hBLVllNzBYb1haNVdzZ3ZNMnRR?oc=5","date":"2026-03-04","type":"pipeline","source":"Seeking Alpha","summary":"Kala Bio rises on plans to leverage AI (KALA:NASDAQ) - Seeking Alpha","headline":"Kala Bio rises on plans to leverage AI (KALA:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNX013LV9HVkszZWtOTU5yQWVUemxhQzAwdFo5Tm1SREJROWR6UmFKWlFQR3AxTmxXcHJlblZpSlI3RVBzSEY3U2YzTXcweXhDQ0dVenc3S3ByM19LLWVySEdYVWtPX2lCczRTcnctUXZoZFFRaEdzLXkxMTRWZWpNTVd4UjRaSXlNWUpjSjVxYk52S25aWUhETmdFdzEwbE5VNFdLV0ZOOVl5MGdTY3dQd1U5THNIc1pYRkRsSA?oc=5","date":"2026-03-04","type":"trial","source":"Stock Titan","summary":"Biotech data stays in-house as KALA BIO bets on on-prem AI for drug R&D - Stock Titan","headline":"Biotech data stays in-house as KALA BIO bets on on-prem AI for drug R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQb1RfWTRQeW9JSmxvMHJUYlpnaXVmbzVQSnFZWlNyT2VaSy1zQjd5M0h0NHIzOU1JdDlMM25YWWNfLUxmS1BhS1lsdnF4S3k3dnpXRmdDODVxb3hyNWxYdFhTeE9Ta0t2Sm4wekdNUlJoSlVRekVGeU1uS3Z5UXJCbWl1TWpJcC1zeHNiSGV3Ung1MzZPUm0tTnpiZF9hWGRTNVlWTkJEeFE?oc=5","date":"2025-12-04","type":"pipeline","source":"Benzinga","summary":"Why Did KALA BIO Shares Jump Over 22% After Hours? - Benzinga","headline":"Why Did KALA BIO Shares Jump Over 22% After Hours?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcUNidWJzam1hN2tYUzhFVjZuazNLTzdSai1nUkJmR0tJNnk1SFZJZDZFS3hHSW1YZWRjTXRobWxoX29lWmtXX09TMmp2b1Vpb3B3TmJLY3Y4OWFQTjJXRXg2bmRTcnNYdnowVExiNWFpY0pidUoxcHRaRms3bHMzaklwREdsYnNmSmo1b0c4dDA5TEZ1N0lqNzhLSG9kR3RVbDdkZHhqakQ?oc=5","date":"2025-11-26","type":"pipeline","source":"Benzinga","summary":"What Sparked KALA BIO's Nearly 38% Surge Overnight? - Kala Bio (NASDAQ:KALA), NovaBay Pharmaceuticals (AM - Benzinga","headline":"What Sparked KALA BIO's Nearly 38% Surge Overnight? - Kala Bio (NASDAQ:KALA), NovaBay Pharmaceuticals (AM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNVHlScV9GQnBCblNpRzZlekV6N19VN2ZBcWpsVXQ5UUdOMDRzME0yOUJWdWMtTEpWc1ZVWHFjbnNVYm1aZVJQSnFNcXZleWl3MUxUbGFXRGdiNmp4eGtTenRCc2JWQS01RlFUNlFYSWs1X2Z1M3oyU0t0ZEpuV2ZUcU1uX3h4bHZreE83YzB2X3pvYmNxeDVrandIZDNaU1hYTnpDdExiS3FIZlhfYms1M19BekNrdW51ZWtIYW9ndW9fTnBPV251ZDE2MGNQQXlmbFl2VEdXSzg0cThhTlA2Qm1xMkczLVJULWdJRy1CVTM5U0IyXzdXSzllRjZRd0FPdnpsR3BaZ3F1MkoxUTdUd3Y0U1Y?oc=5","date":"2025-11-25","type":"trial","source":"Stocktwits","summary":"Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits","headline":"Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Colla","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPdFQ2cE15b2o2U3pNY3dMclBUX3g5V2xaWFRSZ0hjbXJINnFpdlV0OGVWd2NlejRjQUNlVzlFNnVuT1luSXBmdFZ2WkFXajNOYmk5RW1iQVF1eWJ5SmlBM0RxT3pYMEp3QjBGQ2JwalRLMmo5a1E5Tms5cVppcFJPNG53dU9PcWU1ckdKX25n?oc=5","date":"2025-09-30","type":"trial","source":"The Pharma Letter","summary":"Kala Bio tanks on Phase IIb KPI-012 miss - The Pharma Letter","headline":"Kala Bio tanks on Phase IIb KPI-012 miss","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOd01rWmxUVWtaRHhpRURfNklZVkpaNnlXRnZHZFpyREtxNW9aRE9yUjJUTlNmVjRRaDJ6ZXVtSFllTnY2cmlQS05GdVUxNHlxNjc0VDBCb25Yd2Q4WlR5NGFFUDJ4MHZwbmV5Q2h5SmQ1N3hoS0ozMzFscW5NWXFDOUozY3dsdDAxRlZJUXc2aTN2Q25YdWNvRG1ORUZLaXBWWU8yMWRQTDJNa1BNUWpmUHdIcXpQakZfd3NheE5HMA?oc=5","date":"2025-09-29","type":"pipeline","source":"Stocktwits","summary":"Kala Bio Stock Just Plunged 89% Today – Here’s What Happened - Stocktwits","headline":"Kala Bio Stock Just Plunged 89% Today – Here’s What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOcDF3N3RiSzVlSUdCNURpQzhHdDFLOUlTdlJHNUs3alRlQXp4VW1LY2l2S3FtVERLOVdnVl9FXzFUTjVwTHp1ZTlmd3dXXzJhY3phRnBreXpJdEZBMVY1ejIzbDRjdFdGSUxQTXE5c2tNLTdpNkZrbWpyUDlkbGdpMEJaWEJ4eDhlZDBKMndzTE5JRWQzRUNVWFo3bVNOMzhEMTd3NkFBNU5oRkxaTFRDdGIwUHlNa3E5V2h6anR4cExvV2xPYlEwbEpn?oc=5","date":"2025-09-29","type":"trial","source":"Investing.com","summary":"Kala Bio stock plunges after failed Phase 2b trial for eye treatment - Investing.com","headline":"Kala Bio stock plunges after failed Phase 2b trial for eye treatment","sentiment":"negative"}],"patents":[{"drugName":"Eysuvis","drugSlug":"loteprednol-etabonate","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Alcon","Bausch Health"],"therapeuticFocus":["Ophthalmology","Gene Therapy"],"financials":null,"yahoo":null}